NCT02562950 - A Phase I, Open Interaction Study Between GLPG1837 and Midazolam in Healthy Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Healthy

Interventions

DRUG

GLPG1837 500 mg

Each subject will receive multiple oral daily doses of GLPG1837 (250 mg b.i.d. for 11 days) from Days 2 to 12.

DRUG

Midazolam

Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12).

DRUG

GLPG1837 1000 mg

Each subject will receive multiple oral doses of GLPG1837 (500 mg b.i.d. for 11 days) from Days 2 to 12.

Trial Locations (1)

SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp